Kelt:
thanks for digging into this...and it would be useful to get a response from USA Today. In the article from snook, it states the following:
Innovation Pharmaceuticals is evaluating Brilacidin, what is called a defensin mimetic drug candidate, as a potential treatment for coronavirus. The drug has demonstrated antibacterial, anti-inflammatory and immunomodulatory activity in several clinical trials.
Inovio Pharmaceuticals is collaborating with Beijing Advaccine Biotechnology on Inovio’s vaccine, INO-4800, against the coronavirus. It has launched preclinical testing for clinical product manufacturing. It is supported by a $9 million grant from the Coalition for Epidemic Preparedness Innovations (CEPI). Inovio’s INO-4700, an investigational DNA immunotherapy, is also being developed in partnership with GeneOne Life Science. It was originally developed for MERS.
thanks for digging into this...and it would be useful to get a response from USA Today. In the article from snook, it states the following:
Innovation Pharmaceuticals is evaluating Brilacidin, what is called a defensin mimetic drug candidate, as a potential treatment for coronavirus. The drug has demonstrated antibacterial, anti-inflammatory and immunomodulatory activity in several clinical trials.
Inovio Pharmaceuticals is collaborating with Beijing Advaccine Biotechnology on Inovio’s vaccine, INO-4800, against the coronavirus. It has launched preclinical testing for clinical product manufacturing. It is supported by a $9 million grant from the Coalition for Epidemic Preparedness Innovations (CEPI). Inovio’s INO-4700, an investigational DNA immunotherapy, is also being developed in partnership with GeneOne Life Science. It was originally developed for MERS.
1